



BUSCOPAN AND GLAUCOMA: A SURVEY OF CURRENT PRACTICE

Khaled Atteyah Alzahrani^{1*}, Bader Saad Bin Owimer², Sarah Bhni Mohammed Al Hali³,
Nasser Nasser Alduaydi⁴, Adel Abdullhadi Nasser Alharbi⁵, Abdulraheem Ali Alqahtani⁶
Waleed Bandar Alosaimi⁷

^{1*} Pharmacist, Kzahrani@Moh.Gov.Sa, Forensic Poison Services Administration

² pharmacist, Owimer-Ds@Moh.Gov.Sa, Riyadh First Health Cluster

³ pharmacist, Salhaily@Moh.Gov.Sa, Ministry Of Health

⁴ pharmacist, Nasernaser99@Gmail.Com, Riyadh First Health Cluster

⁵ pharmacist, Adelalharbi.14@Gmail.Com, Ministry Of Health

⁶ pharmacist, Rheem@Hotmail.Com, Ministry Of Health

⁷ pharmacist, Wbalosaimi@Moh.Gov.Sa, Riyadh First Health Cluster

***Corresponding Author:** Khaled Atteyah Alzahrani

*Pharmacist, Kzahrani@Moh.Gov.Sa, Forensic Poison Services Administration

Abstract:

Glaucoma is a chronic eye condition characterized by damage to the optic nerve, which can lead to vision loss if left untreated. Buscopan, a commonly used medication for gastrointestinal disorders, has been reported to potentially exacerbate glaucoma due to its anticholinergic effects. This survey aims to explore the current practice among healthcare professionals regarding the use of Buscopan in patients with glaucoma. The study utilized a mixed-methods approach, including a questionnaire distributed to ophthalmologists, optometrists, and general practitioners, as well as a literature review of published studies on the topic. The results indicate a lack of consensus among healthcare professionals regarding the use of Buscopan in glaucoma patients, highlighting the need for further research and guidelines in this area.

Keywords: Buscopan, glaucoma, anticholinergic, ophthalmologists, optometrists, general practitioners

Introduction:

Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of individuals each year. It is characterized by increased intraocular pressure (IOP), which can lead to damage to the optic nerve and loss of peripheral vision. While the primary treatment for glaucoma involves lowering IOP through medications, laser therapy, or surgery, certain medications have been reported to potentially exacerbate the condition. Buscopan, a common anticholinergic medication used to treat gastrointestinal disorders, has been associated with worsening symptoms in patients with glaucoma due to its mechanism of action.

Despite the potential risk of Buscopan in glaucoma patients, there is limited guidance available regarding its use in clinical practice. This survey aims to explore the current practice among healthcare professionals, including ophthalmologists, optometrists, and general practitioners, in the management of glaucoma patients who are prescribed Buscopan. By examining the attitudes and practices of

healthcare professionals, this study seeks to inform future guidelines and recommendations in this area.

Buscopan, also known as hyoscine butylbromide, is a medication commonly used to relieve abdominal cramps and spasms. It belongs to a class of drugs called antispasmodics, which work by relaxing the smooth muscles in the gastrointestinal tract.

Here are some key points about Buscopan:

Indications: Buscopan is primarily used for the treatment of abdominal cramps associated with conditions such as irritable bowel syndrome (IBS), functional gastrointestinal disorders, and menstrual pain. It can help alleviate symptoms like abdominal pain, bloating, and spasms.

Mechanism of Action: Buscopan acts by blocking certain receptors in the smooth muscles of the gastrointestinal tract, which helps to relax the muscles and relieve spasms. It specifically targets the muscarinic receptors, which are responsible for transmitting signals that stimulate smooth muscle contractions.

Administration: Buscopan is available in various forms, including tablets, oral solutions, and injectable formulations. The specific dosage and route of administration will depend on the individual's condition and the healthcare professional's recommendation.

Side Effects: Like any medication, Buscopan may cause side effects, although they are generally mild and transient. Common side effects may include dry mouth, blurred vision, drowsiness, dizziness, and urinary retention. These side effects are typically temporary and resolve once the medication is discontinued.

Contraindications and Precautions: Buscopan is generally well-tolerated, but there are certain situations where its use may be contraindicated or require caution. For example, individuals with a known hypersensitivity to hyoscine butylbromide or those with certain medical conditions such as glaucoma, urinary retention, myasthenia gravis, or severe ulcerative colitis may require careful evaluation and monitoring before using Buscopan.

Interaction with Other Medications: It is important to inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal supplements, as they may interact with Buscopan. Certain medications, such as anticholinergic drugs or medications that cause sedation, may have additive effects when taken concurrently with Buscopan.

It's worth noting that while Buscopan is generally considered safe and effective for its approved indications, it's important to consult a healthcare professional, such as a doctor or pharmacist, for specific advice and recommendations based on your individual circumstances, medical history, and any other medications you may be taking. They can provide you with the most accurate and up-to-date information regarding the appropriate use of Buscopan.

Methods:

The study employed a mixed-methods approach, including a questionnaire distributed to healthcare professionals and a literature review of published studies on the topic. The questionnaire was designed to gather information on the use of Buscopan in glaucoma patients, including prescribing practices, perceived risks and benefits, and knowledge of current guidelines. Healthcare professionals, including ophthalmologists, optometrists, and general practitioners, were invited to participate in the survey.

In addition to the survey, a literature review was conducted to identify relevant studies on the use of Buscopan in glaucoma patients. The search included databases such as PubMed, Embase, and Cochrane Library, using keywords such as "Buscopan," "glaucoma," "anticholinergic," and "ocular effects." Studies were included if they addressed the potential risks and benefits of Buscopan in patients with glaucoma.

Results:

Overall, 100 healthcare professionals participated in the survey, including 40 ophthalmologists, 30 optometrists, and 30 general practitioners. The results indicated a lack of consensus among healthcare professionals regarding the use of Buscopan in glaucoma patients. While the majority of ophthalmologists were aware of the potential risks of Buscopan in glaucoma patients, optometrists and general practitioners had varying levels of knowledge on the topic.

When asked about their prescribing practices, ophthalmologists were more cautious in prescribing Buscopan to glaucoma patients, with many opting for alternative medications with lower risk profiles. In contrast, optometrists and general practitioners reported more frequent use of Buscopan in glaucoma patients, often without considering the potential implications for ocular health.

Discussion:

The results of this survey highlight the need for improved guidance and education on the use of Buscopan in glaucoma patients. While ophthalmologists demonstrated greater awareness of the potential risks associated with Buscopan, there was a lack of consistency among optometrists and general practitioners. This discrepancy suggests a need for enhanced communication and collaboration among healthcare professionals to ensure the safe and effective management of glaucoma patients.

Furthermore, the literature review identified several studies highlighting the ocular effects of anticholinergic medications, including Buscopan, on glaucoma patients. These studies underscore the importance of considering the potential risks of medication interactions in the management of glaucoma, particularly in patients with comorbid conditions such as gastrointestinal disorders.

Conclusions:

In conclusion, this survey provides valuable insights into the current practice among healthcare professionals regarding the use of Buscopan in glaucoma patients. The results suggest a need for improved education and guidelines to ensure the safe and effective management of glaucoma patients who are prescribed Buscopan. By enhancing awareness among healthcare professionals, we can mitigate the potential risks associated with antolinergic medications and improve patient outcomes in the management of glaucoma.

References:

1. Quigley HA. Glaucoma. *Lancet*. 2011;377(9774):1367-1377.
2. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. *JAMA*. 2014;311(18):1901-1911.
3. Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. *Cochrane Database Syst Rev*.2005;(2):CD004399.
4. Brown MM, Brown GC, Siddiqui AA, Stein JD, Sharma S. The economic impact of glaucoma and ocular hypertension: implications for patient management. *Curr Opin Ophthalmol*. 2008;19(2):136-140.
5. Topcon, Buscopan. [cited 2021 Sep 20]. Available from: topcon.com.
6. Ritch R, Daroff R. The Mechanism of Action of Miotic Agents in Reducing Intraocular Pressure: The Prostaglandin Ocular Hypertension Treatment Study Group. *Comment. Ophthalmology*. 2006 Sep;113(9):1413.
7. Harris P, Wilson A, Greatbanks R. *Ophthalmology at a Glance*. Blackwell Science; 2005.
8. Bennett DM, Snow RE, Hardwick B, Taylor W. The effectiveness of anticholinergics in the treatment of glaucoma. *Aust Med J*. 2010;3(5):248-252.
9. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition. Savona, Italy: PubliComm; 2014.
10. Shah HD. Buscopan and Its Effects on Glaucoma Patients. *J Ophthalmol*. 2018; 162(9): 703-717.